ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1473

Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades

Ansaam Daoud1, Loai Dweik2, Marina Nighat Magrey3 and Omer Pamuk4, 1University Hospitals, Case Western Reserve University, Akron, OH, 2Cleveland Clinic Akron General, Akron, OH, 3Case Western Reserve University, University Hospitals, Cleveland, OH, 4University Hospitals Cleveland Medical Center, Cleveland, OH

Meeting: ACR Convergence 2023

Keywords: Mortality, neurology, neuropsychiatric disorders, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are poor prognostic factors in SLE. ACR defined some neuropsychiatric symptoms in SLE. However, their attribution to SLE is challenging due to confounding factors, especially in older populations. Atherosclerotic complications, including cardiovascular and cerebrovascular diseases, are important causes of mortality in patients with SLE. Until now, no study has evaluated nervous system mortality causes in SLE patients. This study investigated nervous system-related mortality in SLE in the past two decades in the USA.

Methods: This retrospective cohort study used the Multiple Cause of Death files maintained by the National Center for Health Statistics to investigate the direction of proportionate nervous system-related mortality in SLE, defined as the number of deaths from diseases of the nervous system (the underlying cause of death: International Classification of Diseases, version 10 [ICD10]: G00-G98), divided by the number of all-cause mortality in patients with SLE (defined in multiple causes of death: ICD10 code M32) from 1999-2020. The data set utilizes death certificate data for US residents. To analyze changes in mortality trends, we separated the study period into two decades, the first decade (1999-2009) and the last decade (2010-2020). Spearman’s correlation test was used for trend analysis, and the Chi-square test was used for comparisons.

Results: 47,337 deaths in SLE occurred during the study period. 814 (1.72%) died of nervous system causes. The mean age for nervous system-related mortality was 69.3 years. Proportionate nervous system-related mortality in SLE was higher in women than men (1.79% vs. 1.34%, p=0.0087), significantly lower in African-American SLE patients than in other races (1.27% vs. 1.93%, p< 0.00001), and lower in Hispanic SLE patients than non-Hispanic patients (1.24% vs. 1.79%, p=0.0034). Proportionate mortality from nervous system disease increased from 1.33% in the first decade (1999-2009) to 2.11% in the second decade (p< 0.00001) (Figure 1). The most common nervous system cause of death in SLE was Alzheimer’s Disease (27%). Table 1 shows other nervous system causes for mortality (Table 1).

Conclusion: This national data showed a significant increase in proportionate mortality from nervous system diseases in SLE. SLE patients in ethnic or racial minority groups seem protected from nervous system-related mortality. Prospective cohort studies are required to understand these trends.

Supporting image 1

Figure 1. Proportionate Nervous System Disease Mortality in SLE Patients Over the Past Two Decades

Supporting image 2

Table 1. Mortality in SLE Patients from Diseases of the Nervous System


Disclosures: A. Daoud: None; L. Dweik: None; M. Magrey: AbbVie, 2, Bristol Myers Squibb, 2, Eli Lilly, 2, Novartis, 2, Pfizer Inc, 2, UCB, 5; O. Pamuk: None.

To cite this abstract in AMA style:

Daoud A, Dweik L, Magrey M, Pamuk O. Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mortality-from-diseases-of-the-nervous-system-in-patients-with-lupus-in-the-past-two-decades/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-from-diseases-of-the-nervous-system-in-patients-with-lupus-in-the-past-two-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology